Novo Nordisk shares slide after semaglutide Alzheimer's trial misses primary goal
Shares of Novo Nordisk (NYSE:NVO) fell sharply on Monday after the Danish pharmaceutical giant said a late-stage trial testing its diabetes and weight-loss drug semaglutide in Alzheimer's disease did not meet its main objective. The Phase III Evoke and Evoke+ trials, which enrolled nearly 3,800 patients with early signs of cognitive decline, showed no meaningful impact on disease progression, Novo Nordisk said.
Failing Drug Stock Suffers Another Blow on Drug Trial Data
Drug maker Novo Nordisk (NYSE:NVO) is sinking 7.8% to trade at $43.87 this morning, earlier hitting a more than four-year low of $43.37 after sharing disappointing trial data for its Alzheimer's drug, semaglutide.
Novo Nordisk stock slides as its Alzheimer's drug trials fail
Novo Nordisk's closely-watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the progression of the brain-wasting disease, the firm said on Monday, a blow to the obesity drug giant that sent its shares sliding.
Novo Nordisk: Semaglutide's Success In Alzheimer's Was Unlikely
Novo Nordisk shares dropped after oral semaglutide failed in phase 3 Alzheimer's trials, ending hopes for this indication. The level of supportive evidence prior to this trial's readout was not high and this was not a surprising outcome. Street expectations for Alzheimer's were low, evidenced in a lack of a bump in revenue estimates for 2027 and beyond.
Will NVO's U.S. Price Cuts Boost Access & Revive Semaglutide Demand?
Novo Nordisk cuts self-pay prices for Wegovy and Ozempic in the United States, aiming to expand access and counter falling demand.
5 Things to Know Before the Stock Market Opens
Stock futures are pointing to a higher open for major indexes to kick off the holiday-shortened trading week; market participants are growing increasingly confident that the Federal Reserve will cut interest rates again next month; bitcoin regained some ground over the weekend after weeks of declines; U.S. officials are in Europe for tariff negotiations; and Ozempic-maker Novo Nordisk's U.S.-listed shares are sinking following the results of its latest drug trial. Here's what you need to know today.
Holiday air travel, Novo Nordisk trial results, 'Wicked: For Good' debut and more in Morning Squawk
Stocks are coming off a losing week, though a Friday rally mitigated declines. U.S. airlines are expecting another record Thanksgiving travel period.
Novo Nordisk Stock Plummets After Ozempic-Maker's Alzheimer's Drug Trial Fails
57.2%. That's how much the company's stock has fallen since the start of 2025. The stock price is now more than 72% below its June 2024 peak, when it breached the Kr 1,000 ($154.5) mark.
Novo Nordisk Shares Slump After Ozempic Pill Fails in Alzheimer's Trials
Oral semaglutide—the ingredient in obesity and diabetes drugs Ozempic and Wegovy—didn't slow Alzheimer's disease in two late-stage clinical trials.
Novo Nordisk shares plunge 10% after Alzheimer's drug trial fails to hit key target
The trial tested whether semaglutide -- the active ingredient in Novo's blockbuster diabetes and weight loss drugs Ozempic and Wegovy -- helped slow progression for Alzheimer's disease. The Novo Nordisk A/S headquarters in Bagsvaerd, Denmark, on Wednesday, Nov. 5, 2025.
Novo's Worst Year Is Your Best Opportunity
I argue that 2025 was the "peak pain" year for Novo Nordisk, and I believe the massive stock correction has gone "too far," creating a compelling GARP opportunity. I believe that despite a guidance cut and pricing pressure, the company's underlying business remains strong, with temporary restructuring costs masking its true profitability. I see major upcoming catalysts, including the launch of an oral version of Wegovy and the 2026 filing for its next-generation drug CagriSema, which I expect will reignite growth.
Novo Nordisk: The Sell-Off Is Getting Absolutely Ridiculous
Novo has experienced a prolonged sell.off over the last months, declining more than 65% from all-time highs. Why some kind of pessimism is justified, the current market cap is way to low considering Novo's presence in two of the most promising healthcare segments. By underlying realistic growth rates, Novo is undervalued by up to 85%.
